Serum Immunoglobulin Changes in Multiple Myeloma Patients Treated with CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed or refractory multiple myeloma (RRMM), with high response rates of 80–95%. Serum immunoglobulin changes have been observed throughout conventional multiple myeloma treatment, including after immunomodula...

詳細記述

書誌詳細

主要な著者:	Alexa Burger, Ulrike Bacher, Michele Hoffmann, Katja Seipel, Christof Schild, Inna Shaforostova, Thomas Pabst
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2025-08-01
シリーズ:	Current Issues in Molecular Biology
主題:	multiple myeloma (MM) CAR T-cell therapy isotype switching immuno-fixation electrophoresis (IFE)
オンライン･アクセス:	https://www.mdpi.com/1467-3045/47/8/640
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!